Company / R&D Expense
Centessa Pharmaceuticals plc R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$172.2M
FY2025
5-year range
$95.7M / $172.2M
FY2021-FY2025
Trend
+14.6%
vs FY2024
Sector context
#92 of 210
Health Care
What the data says
At $172M, Centessa Pharmaceuticals plc's r&d expense ranks #92 of 210 in the Health Care sector. Improved from $124M to $172M over the past 2 years.
Based on SEC 10-K filings.
$172M in FY2025 with a 5-year CAGR of +79.3%.
Improved from $124M to $172M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +3.6%
- 5-Year CAGR
- +79.3%
- 10-Year CAGR
- -
Sector benchmark
#92 of 210 in Health CareTop 44% of 210This company $172.2M Sector average $644.1M
▼
-73.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +79.3%, indicating consistent growth.
- In FY2025, r&d expense increased 14.6% year-over-year.
- Ranks #92 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $172.2M | +14.6% |
| FY2024 | $150.2M | +20.8% |
| FY2023 | $124.4M | -19.8% |
| FY2022 | $155.1M | +62.1% |
| FY2021 | $95.7M | +928.5% |
| FY2020 | $9.3M | +118.2% |
| FY2019 | $4.3M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026